First-trimester pan-immune-inflammation value predicts preeclampsia in a dose-dependent linear pattern
Elevated first-trimester PIV is independently and linearly associated with increased risk of PE, with no identifiable threshold effect. These findings highlight the potential utility of PIV as an accessible, inflammation-based biomarker for early PE risk stratification. Future prospective studies are warranted to validate its clinical applicability and explore integration into prenatal screening protocols.
Authors
- Jieyu Jin
- Wenshi Hu
- Yi Zhu (ORCID: https://orcid.org/0000-0002-8783-319X)
- Longwei Qiao (ORCID: https://orcid.org/0000-0002-5264-9886)
- Sheng Zhang (ORCID: https://orcid.org/0000-0002-8265-9030)
- Yanqiu Zhang (ORCID: https://orcid.org/0009-0007-9603-3155)
- Jun Cao
- Qingqin Tang (ORCID: https://orcid.org/0000-0003-1307-7691)
- Bin Feng (ORCID: https://orcid.org/0000-0001-6262-866X)
- Yuting Liang (ORCID: https://orcid.org/0000-0001-5443-4486)
Institutions
- Jiangsu University (CN)
- Anhui Medical University (CN)
- Fudan University (CN)
- Soochow University (CN)
- University of Chicago Medical Center (US)
- Suzhou Municipal Hospital (CN)
- Molecular Oncology (United States) (US)
- First Affiliated Hospital of Soochow University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- BMC Pregnancy and Childbirth
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1186/s12884-025-08406-1
- Citations
- 2
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 4.11
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province